Research programme: angiopoietin-2 inhibitors - AmgenAlternative Names: L1-10
Latest Information Update: 06 Apr 2011
At a glance
- Originator Amgen
- Class Peptides
- Mechanism of Action Angiopoietin-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Apr 2009 Preclinical trials in Cancer in USA (unspecified route)